日前，知名行业媒体Endpoints News推出了2024“生物医药最具潜力新锐”（Biopharma's Most Exciting Startups in ...

Any company hoping to make headway in the market for obesity therapies will need deep pockets, so it’s an encouraging sign that start-up Metsera has launched with an impressive $290 million in ...

Biopharma startup Metsera turned heads in April when it emerged from stealth, announcing $290 million in funding from prestigious backers—an all-star roster of scientists and executives—and a ...

Metsera, a clinical-stage biotechnology startup that develops drugs for obesity and metabolic diseases, launched on Thursday with what it described as a “broad portfolio” of weight-loss ...

BRIDGEWATER, N.J. & NEW YORK--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, and ...

(RTTNews) - Amneal Pharmaceuticals (AMRX) and Metsera have entered into a collaboration agreement to enable the efficient development and large-scale supply of a portfolio of new weight loss ...

Recommended Reading A gene editing biotech’s struggles end with reverse merger Obesity drug startup Metsera on Tuesday reported its first clinical data since launching in April with $290 million ...

Metsera gains high-quality, efficient, large-scale manufacturing capabilities for its portfolio to enable rapid product development and anticipated commercial launches Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals (NASDAQ:AMRX) entered agreement with Metsera to enable development and large-scale supply of a portfolio of new weight loss medicines globally. Amneal will construct ...

Amneal to construct state-of-the-art manufacturing facilities and utilize existing manufacturing network to ensure supply of Metsera’s portfolio of novel injectable and oral development programs, ...